drugset / Trial / NCT05746728
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of surufatinib combined with tislelizumab in the treatment of metastatic triple-negative breast cancer (TNBC). The study will be conducted in two parts; Safety lead-in phase and dose expansion phase.
Timeline
- Start
- 2023-04
- Primary completion
- 2024-08
- Completion
- 2025-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 200 mg | — |
| Subject | Surufatinib | Small molecule | 250 mg | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |